Bright Minds expands scientific advisory board to support BMB-101 and new Prader-Willi program

Bright Minds Biosciences Inc. (DRUG) — Bright Minds Biosciences announced four additions to its scientific advisory board to support clinical development of its selective 5-HT2C agonist BMB-101 and newly nominated candidate BMB-105, including its recently launched Prader-Willi syndrome (PWS) program.

The move followed the company's early-November initiation of a Phase 2a NOVA study and positioned it ahead of key epilepsy and neurodevelopmental data readouts anticipated in early 2026.

Source: stocktitan.net

For the rest of that week's sector news, read our week in review.